| 引用本文: | 刘小萍,李红,张成,杨雅莉,曾菲,康传哲.胎盘多肽注射液联合化疗对晚期胃癌患者的影响[J].中国现代应用药学,2018,35(9):1384-1387. |
| LIU Xiaoping,LI Hong,ZHANG Cheng,YANG Yali,ZENG Fei,KANG Chuanzhe.Effect of Placenta Polypeptide Injection Combined with Chemotherapy on Patients with Advanced Gastric Cancer[J].Chin J Mod Appl Pharm(中国现代应用药学),2018,35(9):1384-1387. |
|
| 本文已被：浏览 2065次 下载 1397次 |
码上扫一扫！ |
|
|
| 胎盘多肽注射液联合化疗对晚期胃癌患者的影响 |
|
刘小萍,李红,张成,杨雅莉,曾菲,康传哲#
|
|
解放军第452医院药剂科,解放军第452医院药剂科,解放军第452医院药剂科,解放军第452医院药剂科,解放军第452医院药剂科,解放军第452医院药剂科
|
|
| 摘要: |
| 目的 探讨胎盘多肽注射液联合化疗治疗晚期胃癌的临床疗效及安全性，并观察其对晚期胃癌患者免疫功能的影响。方法 随机将2015年5月—2017年5月解放军第452医院收治的78例晚期胃癌患者分为对照组（39例）与观察组（39例），对照组仅采用FOLFOX6化疗方案进行常规化疗，观察组在对照组治疗基础上，加用胎盘多肽注射液。3个疗程后，观察比较2组患者的近期临床疗效、生活质量、免疫功能和不良反应。结果 治疗3个疗程后，观察组患者的总有效率（66.67%）显著优于对照组（53.85%）（P<0.05）；观察组患者生活质量改善情况（Karnofsky评分）及体质量改善情况2项指标均明显优于对照组（P<0.05）；观察组患者的不良反应胃肠道反应、骨髓抑制和白细胞降低的发生率明显低于对照组（P<0.05）。治疗前，2组患者CD3+、CD4+、CD4+/CD8+和NK细胞等免疫功能指标基本无差异；治疗3个疗程后，对照组患者以上免疫功能指标均无明显改变，观察组患者的免疫功能指标除CD8+外均明显提高（P<0.05）。结论 胎盘多肽注射液联合化疗治疗晚期胃癌不仅临床疗效显著，而且可以降低化疗引起的不良反应，并对患者的免疫功能和生活质量具有显著的改善作用。 |
| 关键词: 胎盘多肽注射液 晚期胃癌 化疗 临床疗效 免疫功能 |
| DOI：10.13748/j.cnki.issn1007-7693.2018.09.025 |
| 分类号:R969.4 |
| 基金项目: |
|
| Effect of Placenta Polypeptide Injection Combined with Chemotherapy on Patients with Advanced Gastric Cancer |
|
Liu Xiaoping,Li Hong,Zhang Cheng,Yang Yali,Zeng Fei and Kang Chuanzhe
|
|
1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA,1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA,1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA,1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA,1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA,1The Fourth fifty-two Hospital of the Chinese people's liberation army PLA
|
| Abstract: |
| OBJECTIVE To investigate the clinical efficacy and safety of the placenta polypeptide injection combined with chemotherapy in the treatment of advanced gastric cancer and observe its effect on their immune function. METHODS A total of 78 patients with advanced gastric cancer treated in the 452 Hospital of PLA from May 2015 to May 2017 were randomly divided into control group (39 patients) and observation group (39 patients). Control group was treated with FOLFOX6 chemotherapy alone conventional chemotherapy, observation group treated with the placenta polypeptide injection on the basis of control group's treatment. After 3 courses of treatment, the recent clinical efficacy, quality of life, immune function and adverse reactions were observed and compared in the two groups of patients. RESULTS After 3 courses of treatment, the total effective rate (66.67%) in observation group was significantly better than that in control group (53.85%) (P<0.05). The quality of life improvement (Karnofsky score) and improvement of body mass in the observation group were significantly better than those in the control group (P<0.05). The incidence of gastrointestinal reactions, myelosuppression, and leukopenia were significantly lower in the observation group than in the control group (P<0.05). Before treatment, there were no significant differences in immune function indexes of CD3+, CD4+, CD4+/CD8+ and NK cells between the two groups. After 3 courses of treatment, there were no significant changes in immune function indicators in the control group. In addition to CD8+, other immune function indicators were significantly increased in observation group (P<0.05). CONCLUSION The placenta polypeptide injection combined with chemotherapy for advanced gastric cancer is not only clinically effective, but also can reduce the adverse reactions caused by chemotherapy, and has a significant improvement in the patient's immune function and quality of life. |
| Key words: placenta polypeptide injection advanced gastric chemotherapy clinical efficacy immune-function |
